Clinical Trials Logo

Beta Blocker clinical trials

View clinical trials related to Beta Blocker.

Filter by:
  • None
  • Page 1

NCT ID: NCT06390748 Completed - Sepsis Clinical Trials

Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.

NCT ID: NCT05553314 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Carvedilol in HF With Preserved EF

Start date: November 17, 2021
Phase: Phase 4
Study type: Interventional

Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patients with HF and LVEF of ≥40%, beta-blocker was associated with improved survival in those with low GLS (GLS <14%), but not in those with GLS ≥14%. In this prospective, randomized clinical study, the investigators will assess the effect of slow-release carvedilol in patients with HFpEF and hypertension. The primary endpoint is the time-averaged proportional changes in NT-proBNP level and GLS change from baseline to month 6.

NCT ID: NCT05375240 Not yet recruiting - Stroke Clinical Trials

Propranolol on Post Stroke Immune Status and Infection

Start date: June 2022
Phase: Phase 2
Study type: Interventional

Stroke-associated pneumonia (SAP) is one of the important risk factors influencing poor outcomes and death in stroke patients. Over the past two decades, accumulating evidence suggests that post-stroke brain injury mobilizes the adrenergic system, which induces post-stroke immunosuppression and SAP. This study is designed to test the safety and efficacy of an adrenergic β-receptor blocker, propranolol, with or without combination of antibiotics, in reducing SAP in stroke patients. The underlying immune mechanisms will be investigated.

NCT ID: NCT04748796 Recruiting - Septic Shock Clinical Trials

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

HyperBetashock
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Several data emphasize the relation between tachycardia (>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock. Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.

NCT ID: NCT04264286 Recruiting - Clinical trials for Hemodynamic Instability

The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation

Start date: July 1, 2019
Phase: Phase 4
Study type: Interventional

Beta-blockers are useful tools for the prevention of hemodynamic instability in the manipulation of airways. The main objective of the present study is to evaluate the effectiveness of using esmolol in attenuating hemodynamic responses at the time of tracheal extubation, by assessing the incidence of tachycardia in relation to placebo.

NCT ID: NCT00497003 Completed - Clinical trials for Endothelial Function

Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure

Start date: February 2004
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the effect of the two different beta blockers metoprolol and carvedilol on endothelial function in patients with either type two diabetes or chronic heart failure. Hypothesis: 1* Carvedilol compared to metoprolol has a favourable effect on endothelial function. 2* Carvedilol compared to metoprolol has a favourable effect on insulin stimulated endothelial function. The study is conducted as an open parallel group study. Endothelial function and insulin stimulated endothelial function was evaluated before and after a two months treatment period with either of the two beta blockers.